Saxenda: A New Chapter in Weight Management

Obesity, a global health issue linked to various medical complications, has had its fair share of treatment evolutions. The latest player in the game, Saxenda® (generic name: liraglutide), is positively shifting weight management paradigms.

Developed by Novo Nordisk, Saxenda® is an FDA-approved prescription injectable medicine that, when coupled with a low-calorie meal plan and increased exercise, helps manage obesity. Saxenda® is specifically crafted for chronic weight management in adult patients with a BMI of 27 or more and at least one weight-related health condition, such as hypertension, type 2 diabetes, or high cholesterol.

You cannot copy content of this page